Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026

British pharmaceutical giant GSK Plc (NYSE:GSK) on Wednesday reported upbeat third-quarter results and upgraded its full-year 2025 guidance.

Benzinga

Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms

Incyte Corporation's (NASDAQ:INCY) third-quarter revenue was $1.37 billion. The company beat the consensus of $1.26 billion.

Benzinga

Novartis Maintains Outlook Even As Generics Bite Into Profits

Swiss pharmaceutical major Novartis AG (NYSE:NVS) reported third-quarter 2025 results on Tuesday, reaffirming its full-year guidance as strong sales from key growth drugs offset mounting generic competition in the U.S.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

CSL share price plummets amid shareholder revolt over executive pay plans

US vaccination forecast leads to fall in stock price, while board survives spill in ‘second strike’ over pay concerns at AGM

The Guardian - AU

Avidity Biosciences Soars After $72 Per Share Novartis Takeover

Avidity Biosciences, Inc. (NASDAQ:RNA) stock surged after announcing a $12 billion all-cash acquisition by Novartis AG (NYSE:NVS), marking one of the largest biotech buyouts of the year.

Benzinga

Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday

U.S. stocks were higher, with the Nasdaq Composite gaining around 1% on Monday.

Benzinga

EXCLUSIVE: Co-Diagnostics Inks JV With Saudi Arabia Firm For Middle East Market

Co-Diagnostics, Inc. (NASDAQ:CODX) announced on Monday that it has entered into a joint venture agreement with the Kingdom of Saudi Arabia (KSA) based Arabian Eagle Manufacturing.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal

Avidity Biosciences, Inc. (NASDAQ:RNA) shares are rocketing premarket on Monday. On Sunday, the company agreed to merge with Novartis AG (NYSE:NVS) in a deal valued at $12 billion on a fully diluted basis.

Benzinga

Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket

Shares of Avidity Biosciences Inc (NASDAQ:RNA) rose sharply in pre-market trading after the company agreed to be acquired by Novartis AG (NYSE:NVS).

Benzinga

Biogen's Immunology Pipeline Has Long-Term Potential: Analyst

On Friday, Biogen Inc. (NASDAQ:BIIB) and Vanqua Bio announced a license agreement granting Biogen exclusive worldwide rights to Vanqua's preclinical, oral C5aR1 antagonist. The agreement strengthens Biogen's immunology.

Benzinga

Eli Lilly Bets Big On Eye Gene Therapy That Could End Repeat Injections

Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM) on Friday announced that they have entered into a definitive agreement under which Lilly will acquire Adverum Biotechnologies, including its lead product, Ixo-vec.

Benzinga

Mounjaro Maker Eli Lilly Jumps In Quality Despite Trump-Fueled Price Cut Fears

Eli Lilly and Co. (NYSE:LLY) has surged into the top decile of quality rankings among SP 500 peers, achieving a percentile score of 90.25 on the latest composite quality report, despite fresh uncertainty surrounding the future pricing of its blockbuster weight loss drug, Mounjaro.

Benzinga

Options Corner: A Reliable Quant Signal Just Flashed Again For Pharma Giant Novo Nordisk

At first glance, Novo Nordisk (NYSE:NVO) doesn't appear at all enticing. Down roughly 11% in the trailing month, NVO stock has been a victim of broader market pressure. But it's also the red ink that makes the pharmaceutical giant an enticing opportunity for options traders.

Benzinga

Scienture Holdings Stock Is Soaring Thursday: What's Fueling The Momentum?

Shares of Scienture Holdings, Inc. (NASDAQ:SCNX) are rising Thursday after the comprehensive pharmaceutical product company announced the start of commercial sales for Arbli.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why Is Viking Therapeutics Stock Rising Today?

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) are rising Thursday. The clinical-stage biopharmaceutical company reported third-quarter earnings and provided updates on clinical trials.

Benzinga

Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz

On Wednesday, Alkermes plc (NASDAQ:ALKS) agreed to acquire Avadel Pharmaceuticals plc (NASDAQ:AVDL) for up to $20 per share in cash, which values Avadel at approximately $2.1 billion.

Benzinga

Thermo Fisher's Upbeat Earnings Suggest Worst Is Over For Scientific Tools Sector, Analyst Says

Thermo Fisher Scientific Inc. (NYSE:TMO) on Wednesday reported third-quarter 2025 adjusted earnings of $5.79 per share, beating the street view of $5.49.

Benzinga

4 Biotech Stocks Lifting Off As Momentum Builds

Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands and major indexes reach record levels. Here's a look at four stocks showing notable momentum gains.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Wegovy maker Novo Nordisk’s chair and six other board members step down

Surprise shake-up follows row with majority shareholder, which seeks ‘extensive reconfiguration’

The Guardian - AU

CSL and Optus pay millions to executives despite paying no company tax in Australia

Biotech company argues high pay is required to retain and attract ‘world-class’ talent

International Business Times

Ozempic-maker Novo Nordisk To Shake Up Board

Denmark's Novo Nordisk said Tuesday it would replace more than half of its board, including the chair, as the Ozempic and Wegovy maker restructures in the face of rising competition for its anti-obesity treatments.

Benzinga

What's Going On With Summit Therapeutics Stock On Monday?

Summit Therapeutics Inc. (NASDAQ:SMMT) stock is trading lower on Monday. The company shared progress on its lead drug candidate and third-quarter financial results.

Benzinga

FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times

The Food and Drug Administration announced on Thursday the first round of experimental drugs to be included in a priority voucher program. This FDA initiative is designed to expedite drug review processes for products that align with critical U.S. national health priorities, reducing review times from 10 to 12 months…

Axios

Trump announces plan to lower cost of IVF drugs

The effort would pair two Trump priorities: lowering drug prices and making IVF treatment more affordable.

Benzinga

Vera Therapeutics' Lead Kidney Drug Poised For 2026 Launch In Multi-Billion-Dollar Market

BofA Securities initiated coverage on Vera Therapeutics, Inc. (NASDAQ:VERA), ahead of a key catalyst in 2026 for its lead drug, atacicept, for kidney disease.

1 … 5 6 7 8

People

Lars Fruergaard Jørgensen

18 stories

Mike Doustdar

17 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

the Kingdom of Saudi Arabia

20 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.